Knudsen S T, Foss C H, Poulsen P L, Andersen N H, Mogensen C E, Rasmussen L M
Medical Department M (Diabetes Endocrinology), Institute of Pathology, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark.
Eur J Endocrinol. 2003 Jul;149(1):39-42. doi: 10.1530/eje.0.1490039.
Osteoprotegerin (OPG) is a newly identified inhibitor of bone resorption. Recent studies indicate that OPG also acts as an important regulatory molecule in the vasculature. Plasma levels of OPG seem to be elevated in subjects with diabetes as well as in non-diabetic subjects with cardiovascular disease. The aim of the present study was to examine the association between plasma OPG levels and microvascular complications and glycemic control in patients with type 2 diabetes.
Four groups of 20 subjects in each, individually matched for age and gender, were included in the study: (i) subjects with normal glucose tolerance (NGT); (ii) subjects with impaired glucose tolerance (IGT); (iii) type 2 diabetic patients without retinopathy; and (iv) type 2 diabetic patients with diabetic maculopathy (DMa). Plasma concentration of OPG was measured in duplicate by a sandwich ELISA method. Furthermore, fundus photography, flourescein angiography, and measurements of urinary albumin excretion rate (RIA) were performed.
Plasma OPG was significantly higher in diabetic (iii+iv) than in NGT (i) subjects (3.04+/-0.15 vs 2.54+/-0.16 ng/ml, P<0.05). Plasma OPG was significantly higher in the DMa (iv) group than in the NGT (i) group (3.25+/-0.23 vs 2.54+/-0.16 ng/ml, P=0.01). Moreover, plasma OPG was significantly higher (3.61+/-0.36 ng/ml) in the group of diabetic subjects with both microalbuminuria and DMa (n=7) than in the NGT (i) (2.54+/-0.16 ng/ml, P<0.01), IGT (ii) (2.82+/-0.21 ng/ml, P<0.05), and no retinopathy (iii) groups (2.83+/-0.20 ng/ml, P<0.05).
We found increased levels of OPG in plasma from diabetic patients with microvascular complications. This finding indicates that OPG may be involved in the development of vascular dysfunction in diabetes [corrected].
骨保护素（OPG）是一种新发现的骨吸收抑制剂。近期研究表明，OPG在脉管系统中也作为一种重要的调节分子发挥作用。糖尿病患者以及患有心血管疾病的非糖尿病患者的血浆OPG水平似乎有所升高。本研究的目的是检测2型糖尿病患者血浆OPG水平与微血管并发症及血糖控制之间的关联。
本研究纳入四组受试者，每组20人，年龄和性别个体匹配：（i）糖耐量正常（NGT）的受试者；（ii）糖耐量受损（IGT）的受试者；（iii）无视网膜病变的2型糖尿病患者；（iv）患有糖尿病性黄斑病变（DMa）的2型糖尿病患者。采用夹心ELISA法对OPG的血浆浓度进行双份测定。此外，进行了眼底摄影、荧光素血管造影以及尿白蛋白排泄率（RIA）测定。
糖尿病患者组（iii + iv）的血浆OPG水平显著高于NGT组（i）（3.04±0.15对2.54±0.16 ng/ml，P < 0.05）。DMa组（iv）的血浆OPG水平显著高于NGT组（i）（3.25±0.23对2.54±0.16 ng/ml，P = 0.01）。此外，同时患有微量白蛋白尿和DMa的糖尿病患者组（n = 7）的血浆OPG水平（3.61±0.36 ng/ml）显著高于NGT组（i）（2.54±0.16 ng/ml，P < 0.01）、IGT组（ii）（2.82±0.21 ng/ml，P < 0.05）以及无视网膜病变组（iii）（2.83±0.20 ng/ml，P < 0.05）。
我们发现患有微血管并发症的糖尿病患者血浆中OPG水平升高。这一发现表明OPG可能参与了糖尿病血管功能障碍的发生发展[已修正]。
